Cortech forges ahead against sepsis

Cortech forges ahead against sepsis

Cortech Inc., deciding that the downside exposure has about taken its toll, will expand its new Phase II trial of Bradycor in sepsis to decide conclusively whether the bradykinin antagonist will work against the condition.

Read the full 402 word article

How to gain access

Continue reading with a
two-week free trial.